Goldman Sachs Maintains $205 Price Target on PM — Smoke-Free Pivot Seen as Core Growth Driver

Goldman Sachs reaffirmed its bullish stance on Philip Morris International (PM), maintaining a $205 price target that implies approximately 33% upside from the current share price of around $153. Investors are increasingly watching whether PM can be re-rated from a traditional tobacco company to a growth stock anchored by its smoke-free product portfolio.

Smoke-Free Transition Highlighted as Core Investment Thesis

Goldman Sachs identified PM's shift toward smoke-free products as the central investment case. Smoke-free offerings already account for more than 40% of total revenue, and that share is expected to remain around or above that level through 2028.

Goldman Sachs analyst Bonnie Herzog noted that products such as IQOS are generating a high-growth, high-margin revenue structure, positioning PM as a multi-faceted growth company rather than a purely defensive play. The ongoing portfolio transition is also seen as improving the overall quality of earnings.

ZYN Volume Slowdown Emerges as Key Near-Term Risk

The most pressing near-term concern is the deceleration in U.S. ZYN nicotine pouch volumes. U.S. ZYN volume growth, which reached 36.7% in 2025, is projected to slow to 14.1% in 2026. More notably, Q1 2026 growth is estimated to have plunged to approximately 2.5%, down sharply from 19.3% in the prior quarter.

The market is closely watching whether this slowdown reflects a temporary factor — such as retail inventory destocking or a shift in promotional timing — or signals a more structural softening in demand. The trajectory of ZYN's recovery is seen as having a direct bearing on PM's share price performance.

Margin Expansion and Cost Cuts Serve as Additional Catalysts

Goldman Sachs projects PM's FY2026 operating margin at 41.3%, supported by a favorable product mix shift, pricing power, currency tailwinds, and a $500 million cost reduction program.

If smoke-free products sustain a revenue share above 40% and IQOS profitability continues to improve, the qualitative benefits of the portfolio transformation should become increasingly apparent. A recovery in U.S. ZYN sales would provide further upside to earnings estimates.

Key downside risks remain, however. A prolonged slump in ZYN sales could undermine confidence in PM's growth narrative, while intensifying competition in both the oral nicotine and heated tobacco categories adds pressure. Analysts also caution that favorable currency effects could be flattering reported revenue growth relative to underlying profit improvement.

"PM Must Prove Smoke-Free Growth and Earnings Expansion Simultaneously"

The market broadly finds Goldman's bullish thesis compelling, but views ZYN's recovery and management's ability to execute on margin targets as the ultimate litmus test. Goldman Sachs maintains that if PM can simultaneously demonstrate a growing smoke-free revenue mix and double-digit EPS growth, the stock's current premium valuation would be well justified.